Autoluminescent mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacy

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Zhang, Tianyu ^a,b   Li, Si Yang ^a   Nuermberger, Eric L ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BCG VACCINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BIOLUMINESCENCE; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; EX VIVO STUDY; FEMALE; GENETIC ENGINEERING; GROWTH CURVE; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; LIMIT OF DETECTION; LUNG HOMOGENATE; MICROBIOLOGICAL PARAMETERS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NON INVASIVE MEASUREMENT; NONHUMAN; RELATIVE LIGHT UNIT COUNT; TUBERCULOSIS; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; LUMINESCENCE; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; PATHOGENICITY; TIME; TREATMENT OUTCOME; VIRULENCE;

ANIMALIA; BACTERIA (MICROORGANISMS); MUS; MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; COLONY COUNT, MICROBIAL; FEMALE; LUMINESCENT MEASUREMENTS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS VACCINES; VIRULENCE;

EID: 84855713144     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029774     Document Type: Article

References (27)

1. Andreu N, Zelmer A, Fletcher T, Elkington PT, Ward TH, et al. (2010) Optimisation of bioluminescent reporters for use with mycobacteria. PLoS One 5: e10777.
2. Heuts F, Carow B, Wigzell H, Rottenberg ME, (2009) Use of non-invasive bioluminescent imaging to assess mycobacterial dissemination in mice, treatment with bactericidal drugs and protective immunity. Microbes Infect 11: 1114-1121.
3. Zhang T, Li SY, Converse PJ, Almeida DV, Grosset JH, et al. (2011) Using Bioluminescence To Monitor Treatment Response in Real Time in Mice with Mycobacterium ulcerans Infection. Antimicrob Agents Chemother 55: 56-61.
4. Zhang T, Bishai WR, Grosset JH, Nuermberger EL, (2010) Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains. Antimicrob Agents Chemother 54: 2806-2813.
5. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, et al. (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966.
6. Hickey MJ, Arain TM, Shawar RM, Humble DJ, Langhorne MH, et al. (1996) Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice. Antimicrob Agents Chemother 40: 400-407.
7. Hakkila K, Maksimow M, Karp M, Virta M, (2002) Reporter genes lucFF, luxCDABE, gfp, and dsred have different characteristics in whole-cell bacterial sensors. Anal Biochem 301: 235-242.
8. Snewin VA, Gares MP, Gaora PO, Hasan Z, Brown IN, et al. (1999) Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect Immun 67: 4586-4593.
9. Arain TM, Resconi AE, Hickey MJ, Stover CK, (1996) Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. Antimicrob Agents Chemother 40: 1536-1541.
10. Stover CK, Delacruz VF, Fuerst TR, Burlein JE, Benson LA, et al. (1991) New Use of BCG for Recombinant Vaccines. Nature 351: 456-460.
11. Vilcheze C, Jacobs WR, (2007) The mechanism of isoniazid killing: Clarity through the scope of genetics. Annu Rev Microbiol 61: 35-50.
12. Barry CE, Manjunatha UH, Boshoff H, Dowd CS, Zhang L, et al. (2006) Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 103: 431-436.
13. Horwitz MA, Harth G, (2003) A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 71: 1672-1679.
14. Kong Y, Yao H, Ren H, Subbian S, Cirillo SL, et al. (2010) Imaging tuberculosis with endogenous beta-lactamase reporter enzyme fluorescence in live mice. Proc Natl Acad Sci U S A 107: 12239-12244.
15. Davis SL, Be NA, Lamichhane G, Nimmagadda S, Pomper MG, et al. (2009) Bacterial Thymidine Kinase as a Non-Invasive Imaging Reporter for Mycobacterium tuberculosis in Live Animals. PLoS One 4: e6297.
16. Meighen EA, (1991) Molecular biology of bacterial bioluminescence. Microbiol Rev 55: 123-142.
17. Lee MH, Pascopella L, Jacobs WR, Hatfull GF, (1991) Site-Specific Integration of Mycobacteriophage-L5- Integration-Proficient Vectors for Mycobacterium-Smegmatis, Mycobacterium-Tuberculosis, and Bacille Calmette-Guerin. Proc Natl Acad Sci U S A 88: 3111-3115.
18. Saviola B, Bishai WR, (2004) Method to integrate multiple plasmids into the mycobacterial chromosome. Nucleic Acids Res 32: e11.
19. Nodwell J, Craney A, Hohenauer T, Xu Y, Navani NK, et al. (2007) A synthetic luxCDABE gene cluster optimized for expression in high-GC bacteria. Nucleic Acids Res 35: e46.
20. Hamblin MR, Demidova TN, Gad F, Zahra T, Francis KP, (2005) Monitoring photodynamic therapy of localized infections by bioluminescence imaging of genetically engineered bacteria. J Photochem Photobiol, B 81: 15-25.
21. Szittner R, Jansen G, Thomas DY, Meighen E, (2003) Bright stable luminescent yeast using bacterial luciferase as a sensor. Biochem Biophys Res Commun 309: 66-70.
22. Winson MK, Swift S, Hill PJ, Sims CM, Griesmayr G, et al. (1998) Engineering the luxCDABE genes from Photorhabdus luminescens to provide a bioluminescent reporter for constitutive and promoter probe plasmids and mini-Tn5 constructs. FEMS Microbiol Lett 163: 193-202.
23. Roberts EA, Clark A, Friedman RL, (2005) Bacterial luciferase is naturally destabilized in Mycobacterium tuberculosis and can be used to monitor changes in gene expression. FEMS Microbiol Lett 243: 243-249.
24. Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, et al. (2004) Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 170: 1131-1134.
25. Zhang M, Li SY, Rosenthal IM, Almeida DV, Ahmad Z, et al. (2011) Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am J Respir Crit Care Med 183: 1254-1261.
26. Williams KN, Brickner SJ, Stover CK, Zhu T, Ogden A, et al. (2009) Addition of PNU-100480 to First-Line Drugs Shortens the time Needed to Cure Murine Tuberculosis. Am J Respir Crit Care Med 180: 371-376.
27. Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL, (2009) Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med 180: 1151-1157.